<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094716</url>
  </required_header>
  <id_info>
    <org_study_id>185-7851-201</org_study_id>
    <nct_id>NCT02094716</nct_id>
  </id_info>
  <brief_title>A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group Comparison Study of the Safety and Efficacy of Permethrin Foam, 5% Versus Permethrin Foam, 4% Versus Vehicle in Subjects With Sarcoptes Scabiei</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DPT Laboratories, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foamix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine and compare the safety and efficacy of permethrin foam 4% and permethrin foam 5%
      with that of vehicle in subjects with scabies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is anticipated that a majority of subjects will require and receive a single treatment;
      however, those subjects not showing improvement at the follow-up visit 2 weeks after initial
      treatment will be treated a second time. Those subjects originally assigned to vehicle for
      the first treatment will receive a &quot;re-treatment&quot; with one of the active doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects designated as &quot;treatment success&quot;</measure>
    <time_frame>Day 28</time_frame>
    <description>The primary efficacy variable is &quot;treatment success&quot;. In protocol v2.0, &quot;treatment success&quot; was defined as an IGA score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease-related signs and symptoms</measure>
    <time_frame>Baseline, Day 14, 28, and 42</time_frame>
    <description>The change in the signs/symptoms related to the condition in each treatment group at Days 14 and 28, as well as at Day 42 for those subjects provided with re-treatment at Day 14 who show improvement in their IGA score at Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of re-treated subjects designated as &quot;treatment success&quot;</measure>
    <time_frame>Day 42</time_frame>
    <description>Each subject was designated as &quot;re-treatment success&quot; at Day 42 based upon the criteria in the protocol to which he/she was enrolled (see definitions above)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects designated as &quot;treatment success&quot; following one treatment with an active dose</measure>
    <time_frame>Day 28 and Day 42</time_frame>
    <description>The proportion of subjects designated as &quot;treatment success&quot; (see definitions above) following one treatment versus two treatments. Subjects originally assigned to vehicle treatment and re-treated on Day 14 with an active dose will be included with the single treatment group for this analysis.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Scabies</condition>
  <arm_group>
    <arm_group_label>Permethrin Foam 4%/ Permethrin Foam 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Permethrin Foam 5%/ Permethrin Foam 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Foam / Permethrin Foam 4%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle / Permethrin Foam 5%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Permethrin Foam 4%</intervention_name>
    <description>Topical application, single whole-body treatment</description>
    <arm_group_label>Permethrin Foam 4%/ Permethrin Foam 4%</arm_group_label>
    <arm_group_label>Vehicle Foam / Permethrin Foam 4%</arm_group_label>
    <other_name>PF-045</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Permethrin Foam 5%</intervention_name>
    <description>Topical application, single whole-body treatment</description>
    <arm_group_label>Permethrin Foam 5%/ Permethrin Foam 5%</arm_group_label>
    <arm_group_label>Vehicle / Permethrin Foam 5%</arm_group_label>
    <other_name>PF-055</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Foam</intervention_name>
    <description>Topical application, single whole-body treatment</description>
    <arm_group_label>Vehicle Foam / Permethrin Foam 4%</arm_group_label>
    <arm_group_label>Vehicle / Permethrin Foam 5%</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of active scabies infection.

          -  Subject is in good general health with normal appearing skin in noninfested areas.

          -  Females must be post-menopausal, surgically sterile or use an effective method of
             birth control with a negative pregnancy test (10 years of age and older) at study
             start.

        Exclusion Criteria:

          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.

          -  Subject has used any ectoparasiticide within the three weeks prior to study start.

          -  Subject has signs of systemic infection or is receiving systemic therapy for an
             infectious disease.

          -  Subject has severe cutaneous bacterial or fungal infections requiring therapy or
             heavily crusted lesions consistent with Norwegian scabies.

          -  Subject is currently enrolled in an investigational drug or device study or has used
             an investigational drug or device within 30 days prior to study start.

          -  Subject whose close personal contacts will not comply with standard of care for fomite
             management.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>San Crist√≥bal</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>San Pedro Sula</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Honduras</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <disposition_first_submitted>August 3, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 3, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 8, 2017</disposition_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoptes</keyword>
  <keyword>Scabiei</keyword>
  <keyword>Scabies</keyword>
  <keyword>ectoparasite</keyword>
  <keyword>parasite</keyword>
  <keyword>infestation</keyword>
  <keyword>Renaissance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Permethrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

